State Licensure Requirements
This activity satisfies topic-specific CME/CE requirements (pain management, controlled substances, etc.) of many state licensing boards. Please check with your state’s licensing boards for specific requirements, and print this page as appropriate for documentation. For more information, visit https://www.pri-med.com/state/state-mandated
Iowa: This activity is designed to satisfy requirements of ARNPs, for CE regarding the US Centers for Disease Control and Prevention Guideline for prescribing opioids for chronic pain. Please print this page as documentation, for submission with your CE certificate.
Texas: This activity is approved for Pain Management and Prescription of Opioids requirements from the Texas Medical Board/Board of Nursing, as well as Medical Ethics and/or Professional Responsibility.
This activity satisfies training requirements for the MATE Act, which requires all DEA-registered practitioners to complete 8 hours of CME/CE credit on opioid or other substance use disorders.
Faculty
Charles E. Argoff, MD, FABPM
Vice Chair
Professor of Neurology and Urology
Albany Medical College
Director, Comprehensive Pain Center
Director, Pain Management Fellowship
Albany Medical Center
Albany, New York
Learn More
Oscar A. de Leon-Casasola, MD
Professor of Anesthesiology and Medicine
Senior Vice-Chair
School of Medicine and Biomedical Sciences
University at Buffalo
Chief, Pain Medicine and Professor of Oncology
Roswell Park Cancer Institute
Buffalo, New York
Learn More
Katherine E. Galluzzi, DO, CMD, FACOFP
FACOFP
Professor and Chair
Department of Geriatric and Palliative Medicine
Director, Comprehensive Care
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania
Learn More
Disclosures
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Charles E. Argoff, MD, FABPM: Speaker’s bureau: AbbVie, Amgen, Averitas Pharma, Biohaven, Grunenthal, Impel Pharmaceuticals, Kowa Pharmaceuticals America, Lilly, Lundbeck, Nevro, and Teva. Advisory Board: AbbVie, Amgen, Averitas Pharma, Clexio Biosciences, EnZen Therapeutics, Kowa, Lundbeck, Nevro, Tremeau Pharmaceuticals, Tris Pharma, Vertex and Xgene Pharma. Consultant: Neumentum, PainScript, and Tris Pharma. Researcher: AbbVie, Amgen, Lilly, Lundbeck, and Teva. Stock Holder: Pfizer and Trevena.
Oscar A. de Leon-Casasola, MD: Advisory Board and Consultant: Kowa Pharmaceuticals.
Katherine Galluzzi, DO, CMD, FACOPF: No relevant financial relationships disclosed.
Moderators and non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.